Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia
July 17th 2023Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.
Read More
An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia
June 26th 2023Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.
Read More
The ZUMA-3 Trial: Clinical Endpoints
July 7th 2021Thought leaders in the management of ALL discuss the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy, and lead trial author Bijal Shah, MD, MS, comments on the future application of MRD status.
Read More
The ZUMA-3 Trial: Efficacy and Safety Results
July 7th 2021Primary investigator Bijal Shah, MD, MS, shares insights into the efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and Eunice Wang, MD, reviews the trial’s key safety data.
Read More
The ZUMA-3 Trial: Study Design and Patient Population
July 7th 2021Leukemia experts provide an overview of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy in adult patients with relapsed/refractory acute lymphocytic leukemia (ALL) by discussing the overall study design and patient population.
Read More